Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Malignant Neoplasm
69%
Metastatic Colorectal Cancer
67%
Gastrointestinal Stromal Tumor
66%
Progression Free Survival
62%
Imatinib
58%
Neoplasm
57%
Colorectal Cancer
53%
Chemotherapy
49%
Fluorouracil
45%
Clinical Trial
41%
Phase II Trials
40%
Cetuximab
36%
Disease
33%
Bevacizumab
33%
Folinic Acid
30%
Colon Cancer
24%
Adverse Event
21%
Irinotecan
21%
Leukemia
21%
Recurrent Disease
21%
Cisplatin
18%
Gemcitabine
18%
Disease Free Survival
17%
Paclitaxel
17%
Adenocarcinoma
16%
Nivolumab
16%
Ipilimumab
16%
Oxaliplatin
16%
Randomized Clinical Trial
15%
Pancreas Cancer
15%
Esophagus Cancer
14%
Placebo
13%
Epidermal Growth Factor Receptor
12%
Non Small Cell Lung Cancer
12%
Cytotoxic T Lymphocyte Antigen 4
12%
Diarrhea
11%
Trimetrexate
11%
Celecoxib
11%
Lung Cancer
9%
Protein Tyrosine Kinase Inhibitor
9%
Cohort Study
9%
Chemoradiation Therapy
9%
Erlotinib
8%
Recurrence Free Survival
8%
Stomach Cancer
8%
Biological Marker
8%
Diseases
8%
Neutropenia
8%
Bile Duct Carcinoma
8%
Medicine and Dentistry
Malignant Neoplasm
61%
Overall Survival
60%
Gastrointestinal Stromal Tumor
55%
Oncology
50%
Progression Free Survival
45%
Imatinib
37%
Clinical Trial
36%
Disease
34%
Neoplasm
34%
Colorectal Cancer
33%
Phase II Trials
32%
Rare Tumor
30%
Metastatic Colorectal Cancer
28%
Cetuximab
22%
Surgery
22%
Radiation Therapy
20%
Hazard Ratio
20%
Fluorouracil
20%
Nivolumab
19%
Ipilimumab
19%
Arm
18%
Adverse Event
18%
Targeted Therapy
16%
Cisplatin
15%
Gemcitabine
15%
Recurrent Disease
14%
Cholangiocarcinoma
13%
Chemoradiotherapy
13%
Cancer
13%
Folinic Acid
12%
Esophageal Cancer
12%
Metastatic Carcinoma
12%
Colon Cancer
11%
Adjuvant Therapy
11%
Leukemia
11%
CTLA-4
11%
Adenocarcinoma
11%
Trimetrexate
11%
Non Small Cell Lung Cancer
10%
Placebo
10%
Lung Cancer
9%
Disease Free Survival
9%
Oxaliplatin
8%
Gallbladder Cancer
8%
Irinotecan
8%
Etoposide
8%
Capecitabine
8%
Esophageal Adenocarcinoma
8%
Gallbladder Carcinoma
8%
Recurrence Free Survival
8%
Keyphrases
Gastrointestinal Stromal Tumor
41%
Overall Survival
34%
Phase II Trial
33%
Phase II Study
29%
Progression-free Survival
28%
Imatinib
28%
5-fluorouracil (5-FU)
26%
Southwest Oncology Group
22%
Colorectal Cancer
21%
Leucovorin
21%
Metastatic Colorectal Cancer (mCRC)
21%
Partial Response
21%
Rare Tumors
21%
Metastatic Gastrointestinal Stromal Tumor
19%
PD-1 Blockade
17%
Nivolumab
16%
Ipilimumab
16%
Chemotherapy
16%
Advanced Colorectal Cancer
15%
Basket Trial
15%
Confidence Interval
15%
Imatinib Mesylate
14%
Gemcitabine
14%
Stable Disease
14%
Hazard Ratio
14%
Advanced Gastrointestinal Stromal Tumor
13%
Advanced or Metastatic
13%
Cetuximab
12%
Response Rate
12%
Tumor
12%
Complete Response
11%
Previously Untreated
11%
Median Overall Survival
11%
Group Studies
11%
Celecoxib
11%
Irinotecan
11%
Targeted Therapy
10%
Gallbladder Cancer
10%
Cisplatin
10%
Radiotherapy
9%
Median Survival
9%
Epidermal Growth Factor Receptor
9%
Bevacizumab
9%
Anti-CTLA-4
9%
Adjuvant Therapy
9%
Randomized Clinical Trial
9%
In Cancer
9%
Paclitaxel
9%
Disease-free Survival
8%
Overall Response Rate
8%